Japanese drug maker Daiichi Sankyo says it will take further action to improve quality control at its Ranbaxy unit, following a U.S. ban on ingredients made at a Ranbaxy plant in India.
via WSJ.com: US Business http://ift.tt/1ecIXE3
via WSJ.com: US Business http://ift.tt/1ecIXE3
Nessun commento:
Posta un commento